natgillin/translations-raw huggingface dataset:
The means for allowing air to flow from a proximal end of the adaptor to a distal end of the adaptor independently of the airflow in the conduit when a breath induced low pressure is applied to the distal end of the airflow adaptor are in the form of four second conduits (304, 305, 306, fourth not shown) running from the second circumferential flange (308) to the first circumferential flange (309). 
Inhalator prema zahtjevu 4 gdje je omjer zbroja poprečnih presjeka otvora u drugoj obodnoj prirubnici (208; 308; 508; 705) prema poprečnom presjeku prve cijevi (101; 202; 302; 507; 602; 703) takav da kada se disanjem nastali niski tlak primijeni na distalni kraj adaptora protoka zraka (101; 202; 302; 507; 602; 703) barem 20% nastalog protoka zraka bude kroz otvore.
15-65 weight percent of mannitol, microcrystalline cellulose or a combination of both; 
15-65 masenih postotaka manitola, mikrokristalne celuloze ili njihove kombinacije;
The method according to claim 1, wherein the isolated antibody or antigen binding fragment thereof comprises the three H-CDRs in SEQ ID NO: 21 and the three L-CDRs depicted in SEQ ID NO: 51. 
Humano specifično anti-CD38 antitijelo koje sadrži: H-CDR1, H-CDR2 i H-CDR3 regiju prikazanu u sekvenci SEQ ID NO: 21, i L-CDR1, L-CDR2 i L-CDR3 regiju prikazanu u sekvenci SEQ ID NO: 51;
is optionally present at one or more of the ring atoms, and is selected from the group consisting of hydroxyl, 
R* je izborno prisutan na jednom ili više atoma u prstenu, i izabran je iz grupe koja se sastoji od o
A method of synthesis comprising the steps of, in order: nitrosylation (NOS), in which an N,N-disubstituted-3-optionally substituted aniline, 1, is 4-nitrosylated to give said N,N-disubstituted-3-optionally substituted-4-nitrosyl aniline, 2: 
Diaminofenotiazinski spoj visoke čistoće prema zahtjevu 2 ili 3, naznačen time, da se može dobiti putem postupka sinteze koji obuhvaća sljedeće korake, po redu: nitrozilacija (NOS) u kojoj se N,N-disupstituirani-3-opcionalno supstituirani anilin, 1, 4-nitrozilira kako bi dobio navedeni N,N-disupstituirani-3-opcionalno supstituirani-4-nitrozil-anilin, 2:
LU- is a Linker unit, and 
LU- je jedinica poveznice, i
Therefore the invention also relates to a process comprising reacting 7-ADCA with DHa to form cephradine which is carried out in the presence of an enzyme being an acylase having a higher S/H ratio preferably a higher S/Hini than the wild-type acylase of E.coli and at a temperature of at least 15° C., preferably between 15 and 30° C. Preferably, reacting 7-ADCA with DHa to form cephradine in the presence of an enzyme being an acylase having a higher S/H ratio than the wild-type acylase of E.coli is carried out at a temperature of at least 15° C., preferably between 15 and 30° C. and at a pH of below 7.7, preferably between 6 and 7.5. 
Postupak za pripremanje cefradina, te navedeni postupak sadrži reakciju 7- aminodeacetoksi cefalosporanske kiseline (7-ADCA) s D-dihidrofenilglicinom u aktiviranom obliku (DHa) u prisutnosti enzima u reakcijskoj smjesi da nastane cefradin, što dovodi do pretvaranja 7-ADCA u cefradin od barem 70 %, pri čemu se koncentracija D- dihidrofenilglicina (DH) u reakcijskoj smjesi održava ispod 2 mas.% tijekom reakcije pri čemu navedeni enzim je divlji tip penicilin acilaze, i pri čemu se navedena reakcija provodi na temperaturi ispod 15"C i kod pH od barem 7.0 ili pri čemu navedeni enzim je Pen-G acilaza mutant Phe-24-Ala, te pri čemu se navedena reakcija provodi na temperaturi od barem 15?C i kod pH ispod 7.7.
It may be in the form of a solvate, for example a hydrate, thereof, and may be present in a particular crystalline form. 
Može biti u obliku njihovih solvata, na primjer hidrata i može biti prisutna u zasebnom kristaliničnom obliku.
The pharmaceutical composition for use according to any of embodiments 1-9 wherein the crosslinked amine polymer comprises the residue of an amine corresponding to Formula 2a: 
Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, gdje umreženi aminski polimer sadrži ostatak amina koji odgovara Formuli 2b:
Alternatively, the compounds of this invention may be used in the form of acid or base addition salts. 
spojeve prema ovom izumu može upotrijebiti u obliku kiselih ili bazičnih adicijskih soli.
Characterized in that it includes a sliding corridor (10), within which is arranged slidably said tensioning device (7), said sliding corridor being closed at the front and rear. 
pušku karakterizira klizni put (10) unutar kojega je smješten mehanizam za napinjanje (7) koji se po njemu pomiče klizanjem, dok je sam put zatvoren s prednje 1 zadnje strane.
The composition for use according to any of claims 1 to 4, wherein the dose of desmopressin free base is supplied in the form of the acetate salt of desmopressin. 
Pripravak za uporabu prema zahtjevu 1, 2 ili 3, naznačen time da je doza slobodne baze dezmopresina u obliku acetatne soli dezmopresina.
The anti-Nogo-A antibodies were captured with anti-human IgG (Sigma, #I9764). 
Protutijela protiv Nogo-A uhvaćena su protuljudskim igG (Sigma, br. 19764).
The method of claim 1, wherein the trans-(−)-A9-tetrahydrocannabinol composition comprises at least about 98% by weight of trans-(−)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. The method of claim 4, wherein the trans-(−)-A9-tetrahydrocannabinol composition comprises at least about 99% by weight of trans-(−)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema zahtjevima 1 do 3, naznačen time da sastav trans-(-)-A*-tetrahidrokanabinola sadrži najmanje oko 98% težinski, poželjno najmanje oko 99% težinski i još poželjnije najmanje oko 99.5% težinski trans-(-)-A*- tetrahidrokanabinola bazirano na ukupnoj količini kanabinoida.
The invention relates to the treatment of a disorder of attention, more particularly of attention deficit hyperactivity disorder (ADHD), with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. 
Alfa-fenil(piperidin-2-il)metanol, ili njegove farmaceutski prikladne soli i esteri, posebno acetatni derivat, ili njegova farmaceutski prikladna sol, za uporabu prema jednom od zahtjeva 1 do 4, u liječenju ADHD u odraslih.
7,9,10-Acylation Now, as illustrated in Figure 5 (Scheme 4), the 7-, 9-, and/or 10-positions may be acylated with various groups R7COO, such as those shown in Figure 6. In the compounds shown in Scheme 4, R1, R2, R7, and P1 are as defined above for Schemes 1 and 2, although it should be appreciated that the R7COO groups in Scheme 4 may be different from the R7COO group that was removed in Scheme 1. 
Sada, kao stoje prikazano na slici 5 (shema 4), 7-, 9- i/ili 10-položaj može biti aciliran sa različitim skupinama R;CO0, kao što su oni koji su prikazani na slici 6, u spojevima koji su prikazani na shemama 4, Ri, R;, R7 1 Pi su kao što je gore definirano za sheme 1 i 2, iako treba shvatiti da skupina R;COO u shemi 4 može biti različita od skupine R;COO koja je bila uklonjena iz sheme 1.
The combinations of the invention can optionally comprise one or more additional active substances which are known to be useful in the treatment of respiratory disorders, such as PDE4 inhibitors, leukotriene D4 inhibitors, inhibitors of egfr-kinase, p38 kinase inhibitors and/or NK1-receptor antagonists. 
Kombinacije sukladno predmetnom izumu po izboru mogu sadržavati jednu ili više dodatnih djelatnih tvari koje su poznate kao korisne u liječenju respiratornih poremećaja, poput inhibitora PDE4, B2 agonista ili glukokortikoida, inhibitora leukotnena D4, inhibitora egfr-kinaze, inhibitora p38 kinaze i/ili antagonista NK1-receptora.
The method as claimed in claim 4, wherein the type I collagen has a concentration of 20-50 mg/mL. 
Postupak prema zahtjevu 3, naznačen time, da kolagen tipa I je u koncentraciji od 20 do 50 mg/mL.
The method as claimed in claim 1, wherein said eluting buffer comprises warm water having a temperature ranging from about 45 °C to about 99 °C along with buffer or salt, having a pH ranging from about 8 to about 11, wherein said water is optionally selected from the group consisting of deionized water, DNase free water, RNase free water, MilliQ water, filtered water, tap water and ground water or any combination thereof; wherein said buffer is optionally selected from the group consisting of bicine, tricine, Tris, HEPES, CHAPS, phosphate, acetate, MES, pyridine, piperazine, Bis-tris, PIPES, ACES, BES, TES, borate, TAPS, CHES, CAPS, ethanolamine and piperidine or any combination thereof having a pH ranging from about 5 to about 12; and wherein said salt is optionally selected from the group consisting of MgCl2, CaCl2, NaCl and KCl or any combination thereof in a concentration ranging from about 0.01 mM to about 100 mM, preferably in the range of about 5mM to about 50 mM. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni pufer za eluiranje sadrži toplu vodu, na temperaturi u rasponu od otprilike 45 *C do otprilike 99 "€, uz pufer ili sol, s pH u rasponu od otprilike 8 do otprilike 11, gdje se navedena voda može birati iz skupine koju čine deionizirana voda, voda bez DNaze, voda bez RNaze, MilliQ voda, filtrirana voda, vodovodna voda i podzemna voda ili bilo koja njihova kombinacija; gdje se navedeni pufer može birati iz skupine koju čine bicin, tricin, Tris, HEPES, CHAPS, fosfat, acetat, MES, piridin, piperazin, Bis-tris, PIPES, ACES, BES, TES, borat, TAPS, CHES, CAPS, etanolamin i piperidin ili bilo koja njihova kombinacija s pH u rasponu od otprilike 5 do otprilike 12; te gdje se navedena sol može birati iz skupine koju čine MgCI,, CaC1, NaCl i KCI ili bilo koja njihova kombinacija, u koncentraciji u rasponu od otprilike 0,01 mM do otprilike 100 mM, po mogućnosti u rasponu od otprilike 5 mM do otprilike 50 mM.
The adaptor of claim 8, further comprising a one-way valve (34) at the aerosol outlet port (30). A system (100) for delivering a propelled aerosolized active agent with concomitant positive pressure ventilation to a patient, comprising: 
Sustav (100) za transport aktivnog agensa u formi aerosola do pacijenta uz odgovarajuću ventilaciju pozitivnim tlakom naznačen time da se sastoji od:
Exemplary Functional Assays that Measure the Biological Activity of Compounds that Bind to Extracellular IPT-3 and IPT-4 Domains of HGFR 
Uporaba polipeptida koji sadrži vanstanične IPT-3 i IPT-4 domene receptora faktora rasta hepatocita za pretraživanje farmakološki aktivnih tvari korisnih za liječenje raka.
The compound of claim 1, wherein R3 is a fused heterocyclic group of the formula 
Spoj prema zahtjevu 1, naznačen time, da Rž je staljena heterociklička skupina s formulom: niš
The method, use, therapeutic agent, or IL-21 agonist according to any one of the preceding Claims, wherein the multiple sclerosis is secondary progressive multiple sclerosis. 
Postupak, uporaba, terapijsko sredstvo, ili agonist L-21 prema bilo kojem od prethodnih zahtjeva, naznačen time da multipla skleroza je sekundarna progresivna multipla skleroza.
It also includes a drive system with a cable or a chain attached to the bottom panel, adapted for moving the bottom panel and the panels resting thereon in the height direction. 
- > pogonski sustav s kablom (6) ili lancem pričvršćenim za donju ploču (21), prilagođen da pomiče donju ploču i ploče koje se nalaze na njoj u smjeru visine;
The method according to claim 2 wherein said hydrostatic pressure is applied for a time period between 10 seconds and 150 minutes. 
(b) držanje navedenog biološkog materijala na hidrostatskom tlaku kroz vremensko razdoblje između 10 sekundi 1 150 minuta;
The atypical antipsychotics constitute an important class of drugs for the treatment and prevention of psychotic disorders. 
Atipični antipsihotici sačinjavaju važnu skupinu lijekova za liječenje i prevenciju psihotičnih poremećaja.
The antibody for use of any one of claims 5-8, wherein the antibody comprises an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 55 or 59, wherein X is any amino acid other than S or H. 
SEKVENCE: 28 ili 36; HVR-H3 koji sadrži aminokiselinski slijed IDENTIFIKACIJSKOG BR. SEKVENCE: 55 ili 59, pri čemu je X bilo koja amino kiselina osim S ili H; HVR-L1 koji sadrži aminokiselinski slijed IDENTIFIKACIJSKOG BR.
The system of claim 16, wherein the pressure in the solar greenhouse is 50000 pascal. 
Sustav iz patentnog zahtjeva 8, naznačen time, da je solarni staklenik kuća s mikro tlakom, i tlak u njemu je 50000 paskala.
The method of claim 1, wherein the step a) of estimating the compression quality impact IcodA uses one or more coefficients and/or the bit rate, wherein the one or more coefficients depend on the type of the encoded and/or encrypted audio signal. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se u koraku a) procjene utjecaja kompresije na kvalitetu IcodA upotrebljava jedan ili više koeficijenata ili brzina bita ili jedan ili više koeficijenata i brzina bita, gdje jedan ili više koeficijenata ovise o tipu kodiranog audio signala, ili enkriptiranog audio signala, ili kodiranog i enkriptiranog audio signala.
Method according to any one of claims 1-3, wherein the anti-photogreying additive is present in the photocatalytic dispersion in a range of 1-35 wt.%, preferably 1-15 wt.%, more preferably 1-5 wt.%. 
Postupak prema zahtjevima od 1-3, naznačen time da je aditiv protiv promjene boje pod utjecajem svijetlosti prisutan u fotokatalitičkoj disperziji u rasponu od 1-35% težine, a poželjno je od 1-15% težine, a poželjnije je od 15% težine.
A second, relatively narrow dispensing channel in the filling and dispensing head is connected to a flexible hose that extends at right angles to the longitudinal direction of the container. 
Drugi, relativno uži kanal za raspršivanje u glavi za punjenje i raspršivanje je spojen na fleksibilnu cijev koji se pruža pod pravim kutem u odnosu na uzdužni smjer spremnika.
The antibody or antigen binding portion of claim 5, wherein the EGF-like ligand is selected from the group consisting of EGF, TGF-a, betacellulin, heparin-binding epidermal growth factor, amphiregulin and biregulin. 
Antitijelo ili njegov dio koji se vezuje za antigen u skladu s patentnim zahtjevom 5, naznačeno time što je ligand sličan s EGF odabran iz skupine koja se sastoji od EGF, TGF-a, betacelulina, heparin-vezujućeg epidermalnog faktora rasta, amfiregulina i biregulina.
The composition comprises the ingredients in the following proportion. 
Pripravak ovog izuma obuhvaća sastojke u slijedećim omjerima.
Moreover, a communication method of the invention is a communication method in a mobile station apparatus for which an space of a physical downlink control channel to search is defined based on a mobile station identity assigned from a base station apparatus, and is characterized in that the mobile station apparatus performs decoding processing of a physical downlink control channel including a first mobile station identity and a physical downlink control channel including a second mobile station identity in a search space of a physical downlink control channel corresponding to the first mobile station identity when a plurality of mobile station identities is assigned from the base station apparatus. 
Postupak obrade u uređaju mobilne stanice koji pretražuje prostor pretraživanja za kontrolnim kanalom fizičke silazne veze, PDCCH, koji prenosi uređaj bazne stanice, naznačen time da postupak obrade sadrži: provođenje obrade slijepog dekodiranja, radi pretraživanja prostora pretraživanja za PDCCH, pri čemu je prostor pretraživanja određen na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identiteta druge mobilne stanice; prepoznavanje da se PDCCH koristi za dinamično raspoređivanje kada PDCCH sadrži identitet prve mobilne stanice; te prepoznavanje da se PDCCH koristi za aktiviranje trajnog raspoređivanja kada PDCCH sadrži identitet druge mobilne stanice.
an allergic condition which is triggered by dust mites; 
alergijsko stanje koje iniciraju grinje;
The tetragonal and the cubic phases have higher bulk energy than the monoclinic phase at the standard conditions. 
Tetragonska i kubična faza imaju veću ukupnu energiju od monoklinske faze pri standardnim uvjetima.
reacting compound 99 with an aniline having the formula in the presence of a palladium catalyst, a ligand, and an amide base, to provide compound 100 and 
reakciju spoja 107 i anilina formule [image] u prisutnosti paladija kao katalizatora, liganda fosfina i amidne baze, za dobivanje spoja 108 [image]
The reaction is concentrated in vacuo with toluene and the resulting oil is purified by chromatography on silica eluting with iso-hexane/ethyl acetate (3:1) to yield [2-methyl-1-(4-nitro-benzyl)-1-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid methyl ester. 
Reakcijsku smjesu se koncentrira u vakuumu s toluenom i dobiveno ulje se očisti kromatografijom na silika gelu ispirući s izo-heksan/etil acetatom (3:1), čime se dobije metil ester [2-metil-1-(4-nitro-benzil)-1H-pirolo[2,3-b]piridin-3-il]-octene kiseline.
The pharmaceutical composition as claimed in claim 18, which comprises as a further active ingredient Verapamil, Gallopamil, Fendilin, Diltiazem, Nitrendipin, Felodipin, Amlodipin, Nifedipin, Lercanidipin, Nimodipin, Nicardipin, Lacidipin, Isradipin, Nisoldipin, Nilvadipin or Manidipin. 
Farmaceutski pripravak prema zahtjevu 18, naznačen time da kao dodatni aktivni sastojak sadrži Verapamil, Galopamil, Fendilin, Diltiazem, Nitrendipin, Felodipin, Amlodipin, Nifedipin, Lerkanidipin, Nimodipin, Nikardipin, Lakidipin, Isradipin, Nisoldipin, Nilvadipin ili Manidipin.
The antibody or antigen-binding fragment of any of claims 1-9 for use in treating a B cell related disorder. 
Protutijelo ili antigen-vezujući fragment iz bilo kojeg od patentnih zahtjeva 1-7 za uporabu u liječenju poremećaja povezanog s B-stanicama.
a motor for controlling a movement of the extraction module between the closed and opened state; and 
- < motor (12) za upravljanje s premještanjem modula za ekstrakciju između zatvorenog i otvorenog položaja, i
A pharmaceutical composition comprising a compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži spoj prema bilo kojem od zahtjeva 1-6, ili njegovu farmaceutski prihvatljivu sol, solvat ili hidrat, i farmaceutski prihvatljiv nosač.
not sending, by the target eNB, the special data packet received from the source eNB to the UE. 
slanje, od izvornog eNB, regeneriranog specijalnog paketa podataka prema ciljnom eNB.
Although not visible in FIG. 2, the compression springs 36 are rigidly secured at either end respectively to a part of a latch key and a groove 37 formed in the cylindrical end of jar mandrel 13 thereby preventing complete separation of the latch keys from the jar mandrel 13 in the radial direction. 
I uz to što se ne vidi na Slici 2, kompresijska opruga 36 je čvrsto fiksirana u bilo kojem kraju u odnosu na dio zasuna i šupljine 37 oblikovano u cilindričnom kraju vretena 13 udaraca, čime sprečava potpuno odvajanje zasuna od vretena 13 udaraca u radijalnom pravcu.
the carbon tetrachloride may be present in an amount up to about 50 wt% of the reaction mixture, preferably in an amount from 3 to 30 wt% of the reaction mixture; 
Postupak prema zahtjevu 1, gdje je željezov(III) klorid prisutan u reakcijskoj smjesi u količini u rasponu od 10 do 1000 ppm.
A medical device of claim 21, wherein the medical device is selected from the group consisting of stents, grafts, and implants 
Medicinsko sredstvo prema zahtjevu 20, naznačeno time da je navedeno medicinsko sredstvo izabrano iz grupe koju čine stentovi, transplantati i implantati.
Thus, liquid 4 cannot be discharged from the metering chamber 6 through outlet valve 8 in the first position. 
Tako, dakle, tekućina 4 se u prvom položaju ne može isprazniti iz odmjcerne komore 6 kroz izlazni ventil 8.
The method for hair dyeing or bleaching according to claim 1, wherein the mixed solution discharged in a foam is applied from a hairline or a parted area of hair. 
Postupak bojanja ili izbjeljivanja kose u sklađu s patentnim zahtjevom 1, naznačen time, da se pomiješana otopina koja se izbacuje u obliku pjene nanosi niz vlasi kose ili na razdjeljak kose.
comprises a full-length heavy chain having the amino acid sequence of SEQ ID NO:88, and a full-length light chain having the amino acid sequence of SEQ ID NO:87; or 
(iii) obuhvaća jaki lanac pune duljine, koji ima aminokiselinsku sekvencu SEQ ID NO:88 1 slabi lanac pune duljine, koji ima aminokiselinsku sekvencu SEQ ID NO:87; ili
The pharmaceutical composition according to any one of items 26-29, wherein the pharmaceutical composition is formulated as a hard or soft capsule, a tablet, a syrup, a suspension, an emulsion, a solution, a solid dispersion, a wafer, or an elixir. 
Farmaceutski pripravak prema zahtjevu 6, naznačen time da je farmaceutski pripravak formuliran kao tvrda ili meka kapsula, tableta, sirup, suspenzija, emulzija, otopina, čvrsta disperzija, wafer, ili eliksir.
wherein: Q is a single bond, —O—, —S— or —N(R15)— wherein R15 is hydrogen, C1-3alkyl or C2-3alkanoyl or R15 and R1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring; 
ke naznačen time da: Q je jednostruka veza, -O-, ili pri čemu R? je vodik, C,aalkil ili Cosalkanoil ili R* i R! zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani zasićeni prsten;
Thus, the composition and antimicrobial polypeptide of the invention may be used in the preparation of veterinarian or human therapeutic agents or prophylactic agents for the treatment of microbial infections, such as bacterial or fungal infections, preferably gram positive bacterial infections. 
18. Primjena antimikrobnog polipeptida prema bilo kojem od patentnih zahtjeva 1-9, naznačen time što se koristi u pripremi veterinarskog ili humanog terapeutskog sredstva za liječenje mikorbne infekcije.
Prepare a 30% Sodium hydroxide solution: In a tared bucket, dispense 14 kg of water, purified and carefully add the sodium hydroxide with constant stirring. 
Pripremiti 30% otopinu natrijeva hidroksida: u menziriranu kantu, naliti 14 kg vode, pročistiti i pažljivo dodati natrijev hidroksid uz neprestano mješanje.
A soft chewable composition according to any preceding claim wherein the binder is present at a concentration of about 1 % to about 20% (w/w). 
vezivo je polietilen-glikol ili polivinil-pirolidon, ili njihova kombinacija, i nalazi se u koncentraciji od oko 5% do oko 15% (masa/masa);
The IR, NMR and MS data for Isomer C are set out in Table 2 and the Chiral HPLC and ORD data are set out in Table 4. 
Podaci IR, NMR i MS za Izomer C su prikazani u Tabeli 2 1 podaci za hiralnu HPLC 1 ORD su prikazani u Tabeli 4.
Eliminating atomization to reduce shearing action or trauma that could damage bioactive or chemical substances. 
Isključivanje usitnjavanja kako bi se smanjilo smicanje ili kidanje koji bi mogli oštetiti biološki aktivne ili kemijske supstance. b.
A compound, comprising a peptide and a conjugating group, wherein the peptide comprises an amino acid sequence having the formula: EPMATHMARKEREP wherein 
Spoj, koji obuhvaća peptid i konjugirajuću skupinu, gdje peptid sadrži aminokiselinsku sekvencu formule:
For this reason there should be provided a fertilizer comprising an organic component in addition to the mineral one and making possible a single-step incorporation of the nutrient for the plants in the form of the mineral component and of the organic component for the renewal of the humus in the soil. 
Iz tih razloga korisno je rapolagati s takovim gnojivom, koje pored mineralne komponente, sadrži također i organsku komponentu, te s jednokratnim postupkom gnojenja unositi hranu za biljke u obliku mineralne komponente i organske komponente za obnavljanje humusa u tlu.
Excipients Acacia, Spray-Dried 
Akacija, sušena raspršivanjem